Abstract

When using omics technology to study disease biomarkers, the differences are usually screened between disease group and control group. Because omics data is huge but sample size is limited, the differences between two groups may be randomly generated. To this end, we have proposed a randomized grouping statistical analysis strategy, which is suitable for the study of clinical omics disease biomarkers with limited sample size, and to determine whether the differences between two groups are randomly generated

Keywords

randomized grouping, omics, biomarker